This excerpt taken from the ELN 20-F filed Feb 28, 2007.
Analysis by Segment
Biopharmaceuticals revenue increased 20% to $275.8 million in 2006 from $229.1 million in 2005 and 6% from $259.8 million in 2004. The increase is primarily due to the increase in revenue from increased sales of Maxipime, Azactam and Tysabri, offset by decreases in revenue from divested products. Biopharmaceuticals operating loss decreased 4% to $235.6 in 2006 from $245.4 million in 2005 and 17% from $282.6 million in 2004. The decrease in the operating loss was principally due to the increase in revenues, offset by a decrease in the gain on sale of products and businesses. Biopharmaceuticals net gain on sale of products and businesses decreased to $43.1 million in 2006 (primarily related to the gain on sale of European rights to Prialt) from $103.1 million in 2005 (primarily related to the gains on the sale of Zonegran and our European business). Biopharmaceuticals other net charges increased to $26.3 million in 2006 from $5.6 million in 2005, primarily due to acquired in-process research and development costs incurred in 2006.
EDT revenue increased 9% to $284.6 million in 2006 from $261.2 million in 2005 and increased 28% from $221.9 million in 2004. The increase was due to increased manufacturing revenue and royalties, offset by decreased contract revenue. EDT operating income increased to $69.1 million in 2006 from $47.6 million in 2005 and from $43.6 million in 2004. The increase was primarily due to the increase in revenues and also due to a net other gain of $47.2 million in 2006, which was primarily related to an arbitration award in our favor and against King in 2006.